Skip to main content

Table 4 Odds ratios (95%CI) for the association with left ventricular reverse remodeling

From: Novel myocardial markers GADD45G and NDUFS5 identified by RNA-sequencing predicts left ventricular reverse remodeling in advanced non-ischemic heart failure: a retrospective cohort study

model 1model 2
Age0.99 (0.91–1.08)  
Male Sex0.38 (0.27–5.17)  
Disease duration (months)0.98 (0.96–1.01)  
Height (cm)0.94 (0.81–1.09)  
Weight (kg)0.97 (0.88–1.07)  
HR (bpm)1.01 (0.97–1.06)  
Beta-blocker0.88 (0.05–16.74)  
ACEI or ARB0.38 (0.03–5.17)  
Inotropes0.04 (0.003–0.57)*0.002 (0.001–18.0)0.06 (0.001–2.95)
Hb (g/dL)1.44 (0.86–2.41)  
Cre (mg/dl)0.05 (0.003–1.06)  
BNP (pg/ml)1.00 (0.99–1.01)  
LVDD (mm)0.94 (0.85–1.03)  
LVEF (%)1.06 (0.85–1.32)  
LAD (mm)0.96 (0.86–1.06)  
AR (moderate to severe)1.77 (0.74–4.23)  
MR (moderate to severe)0.61 (0.20–1.93)  
TR (moderate to severe)0.70 (0.26–1.89)  
PAP, mean (mmHg)0.97 (0.88–1.08)  
PCWP, mean (mmHg)0.96 (0.84–1.10)  
RAP, mean (mmHg)0.80 (0.57–1.12)  
CI (L/min/m2)4.75 (0.35–63.67)  
PVR (Wood)0.98 (0.53–1.83)  
NDUFS5 (per 100FPKM)0.07 (0.01–0.92)*0.007 (0.001–7.24) 
GADD45G (per 10FPKM)0.28 (0.09–0.89)* 0.38 (0.13–1.07)
  1. Abbreviations: HR heart rate; ACEI angiotensin converting enzyme inhibitor; ARB angiotensin II receptor blocker; Hb hemoglobin; Cre creatinine; LVDD left ventricular diastolic diameter; LVEF left ventricular ejection fraction; LAD left atrial diameter; AR aortic regurgitation; MR mitral regurgitation; TR tricuspid regurgitation; PAP pulmonary artery pressure; PCWP pulmonary capillary wedge pressure; RAP right atrial pressure; CI cardiac index; PVR pulmonary vascular resistance
  2. aConfounders with p values < 0.05 in each analysis group were included into the model
  3. *p < 0.05